In India, a relief news has emerged in the midst of the ever increasing corona cases. CDSCO Subject Expert Committee on the Vaccine Case approved Russia’s “Sputnik V” for emergency use in India.
Russia’s direct investment fund RDIF and pharmaceutical company Panacea Biotec said on Monday that they will invest 10 million doses of Sputnik V Corona Vaccine annually in India.
According to a joint statement by RDIF and Panacea Biotech, the production of Sputnik V at Panacea Biotech’s manufacturing plants will help RDIF (Russian Direct Investment Fund) international partners to supply this vaccine.
RDIF CEO (CEO) Kirill Dmitriev said, “Cooperation with Panacea Biotech is an important step in terms of vaccine production in India and supply to international partners.
Panacea Biotech Managing Director Rajesh Jain said that the company will produce Sputnik V in internationally recognized plants
Now in India, now covishield, covaxin against Corona virus, now Sputnik V can also be used.
According to the sources, trial data has been presented by Sputnik, on the basis of which these approvals have been obtained.
However, the government will clarify the situation on this by evening itself.
The efficacy of the Russian vaccine was revealed to be 91.6 percent in an interim analysis of the Phase III trial. It was tested on 19,866 people in Russia.
According to the Sputnik website, the final phase was tested in the UAE, India, Venezuela and Belarus.
Sputnik vaccine has been approved at a time when many states are being accused of not supplying enough medicine to the Center.
In such a situation, after the introduction of this vaccine, it is expected that the war of vaccination against Corona in India will be further intensified.